Overview

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

Status:
RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

Phase:

PHASE1

Details

Lead Sponsor:

Pacira Pharmaceuticals, Inc

Treatments:

Bupivacaine